Cuál es el precio por Brii Biosciences Limited (2137)

Precio por Brii Biosciences Limited (2137) es de$0.12984512

Cuál es la capitalización de mercado por Brii Biosciences Limited (2137)

Capitalización de mercado por Brii Biosciences Limited (2137) es $93.64M

Brii Biosciences Limited (2137) Ratio P/B

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

Año	Ratio P/B	Cambiar
Not enough data for the provided dates.

Año

Ratio P/B

Cambiar

Not enough data for the provided dates.

Empresa	Ratio P/B	Diferencia del ratio P/B	País
Vertex Pharmaceuticals Incorporated VRTX.US	6.3419	-	US
Argenx SE ARGX.US	6.2413	-	NL
Moderna, Inc. MRNA.US	3.7087	-	US
CSL Limited CSL.AX	2.5054	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

Ratio P/B

Diferencia del ratio P/B

País